Portal Range Monitoring in Mixed Ion Beam Surgery
PROMISE aims to revolutionize carbon ion radiotherapy by developing mixed ion beams for real-time tumor monitoring, enhancing treatment precision and potentially improving patient outcomes.
Projectdetails
Introduction
Half of the approximately 4 million annual cancer cases in Europe receive radiotherapy. While many cancer patients have benefitted from technical improvements in recent years, widespread diseases, such as pancreatic and lung cancer, still have dismally low cure rates, with median survival of less than 2 years.
Carbon Ion Radiotherapy (CIRT)
Carbon ion radiotherapy (CIRT) offers unprecedented precision in delivering tumour dose and can be the much-needed game changer for these patients. However, CIRT is vulnerable to uncertainties in patient positioning, anatomy changes, and organ motion.
Current Challenges
The current clinical approach is to increase the high dose volume to ensure target coverage, counteracting the primary advantage of CIRT. Novel strategies for image guidance and beam range assessment are crucial to unlock the full potential of CIRT for the best possible patient care.
PROMISE Project
PROMISE, for the first time, will produce mixed ion beams that enable concurrent treatment and image guidance.
How It Works
- Carbon ions deliver the dose to the target.
- Helium ions, simultaneously accelerated to the same velocity, traverse the patient and monitor tumour location and beam range.
PROMISE realizes true portal imaging, providing real-time information on the target anatomy as seen by the treatment beam. Coupled with innovative detectors, AI-based image recognition, and online dose reconstruction, this technique will enable a drastic reduction in safety margins and achieve the full potential of CIRT.
Development and Validation
The GSI accelerators are uniquely suited to develop the first mixed beam of Carbon and Helium, along with strategies for their cost-effective translation to existing and future clinical CIRT centres.
Experimental Validation
- The method will be validated experimentally in GSI’s former CIRT treatment room.
- Patient simulation studies will highlight clinical benefit and characterize ideal use cases.
- A demonstration in an animal model will pave the way for clinical transition.
Conclusion
The mixed beam image guidance of PROMISE will lead to a paradigm shift in CIRT.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.000.000 |
Totale projectbegroting | € 2.000.000 |
Tijdlijn
Startdatum | 1-3-2024 |
Einddatum | 28-2-2029 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- GSI HELMHOLTZZENTRUM FUR SCHWERIONENFORSCHUNG GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Prompt Gamma Time Imaging: a new medical-imaging modality for adaptive Particle TherapyThe project aims to enhance particle therapy efficacy and safety by developing Prompt Gamma Time Imaging for real-time monitoring of treatment, improving dose control and adaptive dosimetry. | ERC Starting... | € 1.498.969 | 2022 | Details |
Gamma-Neutron Vision aimed at improved cancer treatments in Hadron TherapyThis project aims to develop a portable device for simultaneous gamma-ray and thermal neutron imaging to enhance ion-range verification and secondary neutron dose assessment in proton therapy. | ERC Proof of... | € 150.000 | 2024 | Details |
Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRIDevelop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics. | ERC Starting... | € 1.497.669 | 2024 | Details |
Nanoscintillators to potentiate brain cancer radiotherapy: from physics to preclinical trialsThis project aims to enhance radiation therapy for glioblastoma by studying nanoscintillators' effects on tumor tissues, improving treatment efficacy while minimizing damage to healthy cells. | ERC Starting... | € 1.948.125 | 2024 | Details |
Hybrid Imaging in the Catheterization RoomThis project aims to evaluate the IXSI c-arm scanner's potential in interventional cardiology to enhance treatment outcomes and develop a viable business case for its clinical application. | ERC Proof of... | € 150.000 | 2023 | Details |
Prompt Gamma Time Imaging: a new medical-imaging modality for adaptive Particle Therapy
The project aims to enhance particle therapy efficacy and safety by developing Prompt Gamma Time Imaging for real-time monitoring of treatment, improving dose control and adaptive dosimetry.
Gamma-Neutron Vision aimed at improved cancer treatments in Hadron Therapy
This project aims to develop a portable device for simultaneous gamma-ray and thermal neutron imaging to enhance ion-range verification and secondary neutron dose assessment in proton therapy.
Transformative Pediatric Brain Cancer Imaging using Integrated Biophysics-AI Molecular MRI
Develop a novel AI-driven molecular MRI technology for rapid, noninvasive monitoring of pediatric brain cancer treatment response, enhancing precision medicine and understanding of tumor dynamics.
Nanoscintillators to potentiate brain cancer radiotherapy: from physics to preclinical trials
This project aims to enhance radiation therapy for glioblastoma by studying nanoscintillators' effects on tumor tissues, improving treatment efficacy while minimizing damage to healthy cells.
Hybrid Imaging in the Catheterization Room
This project aims to evaluate the IXSI c-arm scanner's potential in interventional cardiology to enhance treatment outcomes and develop a viable business case for its clinical application.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Treatment planning assessment for the Optiflux radiosurgery systemDit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen. | Mkb-innovati... | € 20.000 | 2021 | Details |
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid TumoursScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027. | EIC Transition | € 2.499.911 | 2025 | Details |
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy. | EIC Pathfinder | € 5.972.875 | 2024 | Details |
Very High Energy Electrons Beam for RadiotherapyeBeam4Therapy aims to revolutionize cancer treatment by developing compact, cost-effective VHEE radiotherapy using laser plasma accelerators to improve patient outcomes and reduce side effects. | EIC Transition | € 2.477.043 | 2022 | Details |
NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPYThe NOVO project aims to develop a groundbreaking real-time dose verification technology for proton radiotherapy, enhancing personalized cancer treatment and improving patient outcomes. | EIC Pathfinder | € 3.759.489 | 2024 | Details |
Treatment planning assessment for the Optiflux radiosurgery system
Dit project ontwikkelt een innovatieve radiotherapie met sub-MeV X-stralen voor nauwkeurige tumorbehandeling en minder schade aan omliggende organen.
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours
ScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027.
Development of innovative proton and neutron therapies with high cancer specificity by 'hijacking' the intracellular chemistry of haem biosynthesis.
NuCapCure aims to develop novel cancer treatments for glioblastoma by utilizing custom-made drugs through biosynthesis to enhance proton and neutron therapies for better targeting and efficacy.
Very High Energy Electrons Beam for Radiotherapy
eBeam4Therapy aims to revolutionize cancer treatment by developing compact, cost-effective VHEE radiotherapy using laser plasma accelerators to improve patient outcomes and reduce side effects.
NEXT GENERATION IMAGING FOR REAL-TIME DOSE VERIFICATION ENABLING ADAPTIVE PROTON THERAPY
The NOVO project aims to develop a groundbreaking real-time dose verification technology for proton radiotherapy, enhancing personalized cancer treatment and improving patient outcomes.